Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Arcus Biosciences, Inc. (NYSE: RCUS) on December 12, 2019, reporting events occurring on December 10, 2019. The filing addresses corporate governance changes under Item 5.02.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on director appointments and compensation arrangements.
Material Changes
The Board of Directors appointed Patrick Machado as a Class I Director. He was also appointed to the Nominating and Corporate Governance Committee. No financial material changes were reported in this document.
Guidance, Outlook, and Compensation Details
Mr. Machado's compensation package includes:
- Annual cash retainer of $35,000 for Board service.
- Annual cash retainer of $4,000 for Nominating and Corporate Governance Committee service.
- Option to purchase 50,000 shares of common stock, vesting in equal monthly installments over 36 months.
- Accelerated vesting provisions apply in the event of a Change in Control.
The filing states there are no other arrangements or understandings regarding his selection and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
Investor Verification Checklist
- Verify the vesting schedule and exercise price of the 50,000 stock options granted to Patrick Machado.
- Confirm the total number of directors on the Board following this appointment.
- Review the Company's Director Compensation Program for details on Change in Control definitions.